Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Inventory: 2018-2025

Historic Inventory for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $28.0 million.

  • Catalyst Pharmaceuticals' Inventory rose 40.03% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 40.03%. This contributed to the annual value of $19.5 million for FY2024, which is 24.91% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Inventory stood at $28.0 million, which was up 50.29% from $18.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Inventory registered a high of $28.0 million during Q3 2025, and its lowest value of $4.4 million during Q1 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Inventory value was $18.6 million (recorded in 2025), while the average stood at $17.2 million.
  • Its Inventory has fluctuated over the past 5 years, first spiked by 288.25% in 2021, then decreased by 13.53% in 2022.
  • Catalyst Pharmaceuticals' Inventory (Quarterly) stood at $7.9 million in 2021, then fell by 13.53% to $6.8 million in 2022, then skyrocketed by 129.89% to $15.6 million in 2023, then rose by 24.91% to $19.5 million in 2024, then skyrocketed by 40.03% to $28.0 million in 2025.
  • Its Inventory stands at $28.0 million for Q3 2025, versus $18.6 million for Q2 2025 and $19.8 million for Q1 2025.